AS MEDICAL RADIATION EXPOSURE RISES, LOWERING PERIPHERAL DOSE FROM RADIOSURGERY TAKES ON NEW IMPORTANCE

AS MEDICAL RADIATION EXPOSURE RISES, LOWERING PERIPHERAL DOSE FROM RADIOSURGERY
TAKES ON NEW IMPORTANCE

PRESS RELEASE	
Stockholm, Sweden, June 26, 2007


A recent study that reveals Americans have experienced a six fold increase in
radiation since 1980 from medical devices is giving new impetus to reducing
peripheral dose. It is one reason that radiosurgery centers are clamoring for
the new Leksell Gamma Knife® Perfexion™ - the system reduces excess radiation
dose to the body up to 100 times compared to competing linac-based technologies.

The study, conducted by the National Council on Radiation Protection and
Measurement, attributes much of the increase to CT scanning, which accounts for
nearly half of the medical radiation dose delivered in the U.S. despite making
up just 12 percent of medical and radiation procedures in the country. 

“The fundamental principles of radiosurgery are to deliver a highly focused
amount of radiation to the target while minimizing the dose given to the
surrounding tissues through a steep fall-off. No where are these tenets more
important than the field of intracranial radiosurgery,” said Jason Sheehan,
M.D., Ph.D., and Associate Director of the Lars Leksell Gamma Knife Center at
University of Virginia. “Maximizing delivery to the target volume and affording
a low peripheral dose will translate into improved outcomes, as well as, reduced
morbidity.”

Focus on Safety

Patient and staff safety was a key consideration during the development of
Leksell Gamma Knife Perfexion. Not only is reducing excess radiation critically
important when treating children and women of childbearing age, it also allows
patients with other cancers to continue their radiotherapy uninterrupted rather
than wait six weeks after a less precise treatment. 

The accuracy of Gamma Knife surgery is closely tied to the use of a stereotactic
frame. The frame attaches to a patient's head with four pins and is present
during the one MRI imaging scan as well as treatment. Use of the frame
eliminates the need to fractionate, or spread treatment out for several days, as
often is the case with other technologies.

Building a Better Treatment System

Leksell Gamma Knife Perfexion was developed in conjunction with leading
neurosurgeons to be:
• Precise - Thousands of radiation beams converge, during a single treatment
session, with a level of accuracy better than 0.5mm, about the thickness of a
strand of hair, leaving nearby healthy tissue undamaged.
• Proven - With almost 500,000 patients treated worldwide, and thousands of
peer-reviewed scientific articles, the system has unmatched clinical experience.
• Streamlined - The fully automated system is expected to save many hours of
total physician and staff time - equaling one day every two weeks - while
allowing speedy treatment of multiple brain metastases and complex targets.

Preferred by Neurosurgeons

Gamma Knife surgery has become the world's most widely used radiosurgery
treatment for brain disorders due to its extraordinary accuracy, reduction of
excess radiation dose to the body and extensive history and superior clinical
results. Unlike some systems which are used for the whole body, Leksell Gamma
Knife is specifically designed to optimize treatment to the head - a fact
appreciated by neurosurgeons and patients alike.

With unmatched accuracy and single-dose treatments, non-invasive Gamma Knife
surgery is preferred by neurosurgeons over less precise linac systems and whole
brain radiotherapy, which deliver much higher doses of excess radiation to the
body. Treatment is completed in a matter of hours and most patients go home the
same day to resume normal activities.


Related Links:
www.Elekta.com
www.BrainTumorTreatment.org
www.irsa.org


******

For further information, please contact:

Media inquiries: Michelle Lee, PR and Advertising Manager, Tel: +1 770-670-2447,

e-mail: michelle.lee@elekta.com

Investor inquiries: Peter Ejemyr, Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com  

About Elekta

Elekta is an international medical-technology Group, providing meaningful
clinical solutions, comprehensive information systems and services for improved
cancer care and management of brain disorders. All of Elekta's solutions employ
non-invasive or minimally invasive techniques and are therefore clinically
effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April
2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world
to treat cancer and manage clinical operations as well as to diagnose and treat
brain disorders, including tumors, vascular malformations and functional
disorders. 

With approx. 2,000 employees, Elekta's corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.